Tafenoquine succinate inhibits the growth of the equine piroplasmosis hemoparasites Theileria equi and Babesia caballi
Key Points
Inhibition of T. equi and B. caballi growth demonstrates tafenoquine's potential as an alternative therapy.
Significant reductions in hemoparasite proliferation observed at doses safe for equine PBMCs.
Assessment using equine peripheral blood mononuclear cells (PBMCs) highlights the treatment's effectiveness.
Supports further research on tafenoquine for in vivo applications in treating equine piroplasmosis.
Abstract
TFQ significantly inhibited T. equi and B. caballi growth at doses tolerated by equine PBMCs, supporting its potential as an alternative treatment for EP and warranting further in vivo study.